MARKET

TNXP

TNXP

Tonix Pharmaceut
NASDAQ
0.1755
+0.0010
+0.57%
After Hours: 0.1785 +0.003 +1.71% 19:56 05/24 EDT
OPEN
0.1800
PREV CLOSE
0.1745
HIGH
0.1859
LOW
0.1601
VOLUME
2.82M
TURNOVER
0
52 WEEK HIGH
3.313
52 WEEK LOW
0.1202
MARKET CAP
16.77M
P/E (TTM)
-0.0317
1D
5D
1M
3M
1Y
5Y
TONIX PHARMACEUTICALS HOLDING CORP: PLANS TO REDUCE ITS WORKFORCE BY 23 FULL-TIME EMPLOYEES
Reuters · 5d ago
Tonix Pharmaceuticals To Deliver Oral Presentation And Presents Two Posters At The ASCP Annual Meeting May 28-31, 2024
Tonix Pharmaceuticals Holding Corp. Will deliver an oral presentation and present two posters at the American Society of Clinical Psychopharmacology Annual Meeting being held May 28-31, 2024 in Miami Beach, Florida. The Company will present its TNX-102 SL program for Fibromyalgia.
Benzinga · 5d ago
Tonix Pharmaceuticals Reports Key Findings From Initial Phase Of EVERSANA Market Opportunity Analysis For Tonmya For The Management Of Fibromyalgia
Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia. New Drug Application (NDA) submission to the FDA on track for the second half of 2024. EVERSANA completed the initial phase of an assessment of the market opportunity for Tonmya.
Benzinga · 6d ago
TONIX PHARMACEUTICALS HOLDING CORP - NEW DRUG APPLICATION (NDA) SUBMISSION TO FDA ON TRACK FOR SECOND HALF OF 2024
Reuters · 6d ago
Weekly Report: what happened at TNXP last week (0513-0517)?
Weekly Report · 05/20 11:25
Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
Seth Lederman will participate virtually in a fireside chat at Tonix Pharmaceuticals Holding Corp.’s Healthcare Company Showcase on May 21, 2024. Tonix is a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates.
Barchart · 05/15 07:00
Financial Report Articles: Q1 2024 - Usage of Assets and Liabilities
Press release · 05/14 02:03
Tonix Pharmaceuticals GAAP EPS of -$0.18 beats by $0.16, revenue of $2.48M misses by $1.39M
Seeking Alpha · 05/13 21:11
More
About TNXP
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.

Webull offers Tonix Pharmaceuticals Holding Corp stock information, including NASDAQ: TNXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNXP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TNXP stock methods without spending real money on the virtual paper trading platform.